A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Grazoprevir (MK-5172) in Hepatitis C Infected Male Patients
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Jul 2012 Planned end date changed from 1 Aug 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.